The Motley Fool

Should you buy Neil Woodford’s favourite small caps Purplebricks Group plc, 4d Pharma plc and Imperial Innovations Group plc?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Hybrid online estate agent Purplebricks (LSE: PURP) is an estate agency disruptor and certainly ranks highly in the eyes of Neil Woodford as his funds own more than 25% of the company’s outstanding shares. And judging by Purplebricks’ latest annual results, this wasn’t a bad move at all as annual revenue jumped a whopping 448% and website visits more than tripled due to major investments in marketing and sales campaigns.

Of course, beefed-up marketing campaigns haven’t come cheap and are the reason pre-tax losses doubled to £10.5m. However, as seen with the jump in revenue, increased awareness has filtered through to higher sales and management expects to turn its first profit in fiscal year 2017. This would be a huge step for a company that is barely two years old and still has massive disruptive potential for the stodgy traditional estate agent model.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Purplebricks, rather than taking a commission on each property sale of up to 2.5%, offers simple flat-fee packages that are payable whether or not the sale goes through. The low fixed fees combined with the benefit of working with a self-employed local estate agent is what sets Purplebricks apart from both traditional agents and other online-only competitors. If the company can keep up the pace of breakneck growth, maintain 60%-plus market share among online competitors, and doesn’t rush its planned expansion into Australia, Purplebricks definitely has a place on my watch list.


Neil Woodford’s interest in disruptive companies is also apparent with his 24% stake in biotherapeutics firm 4D Pharma (LSE: DDDD). Biotherapeutics is a burgeoning field that seeks to harness the benefits of live organisms such as gut bacteria to treat a variety of illnesses that have thus far defeated traditional pharmacology.

4D’s initial focus has been on gut bacteria and diseases in the related area, such as Crohn’s, colitis and irritable bowel syndrome. Progress has been picking up lately and the company now has several of its 15 treatments progressing through clinical trials.

Despite currently having no revenue, 4D is well placed to continue investing in its pipeline due to £85.4m in cash against total annual pre-tax losses last year of only £10.1m. But while the company’s financial position is appealing and biotherapeutics have massive upside, investing in a small pharma company that currently has no approved products or revenue is just too risky a proposition for me.

Trust in Woodford?

It’s a similar story for another of Neil Woodford’s most concentrated holdings, his 21% stake in Imperial Innovations (LSE: IVO). It has ties with universities and researchers across the UK and invests in start-ups in industries as varied as novel oncology treatments to remote sensors for oil & gas facilities.

With stakes in 38 companies, many of them early stage private ventures, investing in Imperial Innovations requires placing high amounts of trust in the fund managers to choose their investments well. Without the expertise necessary to judge the prospects of starts-ups focused on everything from the treatment of viral infections after bone marrow transplants to next generation lithium ion batteries, Imperial Innovations isn’t at the top of my buy list despite Neil Woodford’s bullishness.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Ian Pierce has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.